Combining targeted therapy with immunotherapy (interferon-α) rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 773-776

  Chen, Lei L ^a   Gouw, Launce ^a   Sabripour, Mahyar ^b   Hwu, Wen Jen ^c   Benjamin, Robert S ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Agensys Inc   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Drug resistance; Gastrointestinal stromal tumor; Imatinib; Immunotherapy; Interferon a; Peginterferon a 2b; Targeted therapy

Indexed keywords

IMATINIB; IPILIMUMAB; MDX 1105; MONOCLONAL ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; UNCLASSIFIED DRUG; VEMURAFENIB;

ARTICLE; B RAF GENE; CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; HEMATOLOGIC MALIGNANCY; INOPERABLE CANCER; KAPOSI SARCOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; VIRUS HEPATITIS;

EID: 84886944075     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19729     Document Type: Article

References (10)

1. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 2002; 38(Suppl 5): S19-27; PMID:12528769; http://dx.doi.org/10.1016/S0959-8049(02)80599-8
2. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26:5360-7; PMID:18955451; http://dx.doi.org/10.1200/JCO.2008.17.4284
3. Ribas A, Kim KB, Schuchter LM, Gonzalez R, Pavlick AC, Weber JS, et al. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011; 29S:8509.
4. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64:5913-9; PMID:15342366; http://dx.doi.org/10.1158/0008-5472.CAN-04-0085
5. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011; 364:772-4; PMID: 21345109; http://dx.doi.org/10.1056/NEJMcibr1013704
6. Chen LL, Chen X, Choi H, Sang H, Chen LC, Zhang H, et al. Exploiting antitumor immunity to overcome relapse and improve remission duration. [Epub ahead of print]. Cancer Immunol Immunother 2011; PMID: 22198309
7. Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, et al. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol 2009; 182:7398-407; PMID:19494262; http://dx.doi.org/10.4049/jimmunol.0802982
8. Huber JP, Farrar JD. Regulation of effector and memory T-cell functions by type I interferon. Immunology 2011; 132:466-74; PMID:21320124; http://dx.doi.org/10.1111/j.1365-2567.2011.03412.x
9. Ma Y, Conforti R, Aymeric L, Locher C, Kepp O, Kroemer G, et al. How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev 2011; 30:71-82; PMID:21298323; http://dx.doi.org/10.1007/s10555-011-9283-2
10. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29:482-91; PMID:19881547; http://dx.doi.org/10.1038/onc.2009.356